KR20240001198A - Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스 - Google Patents

Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스 Download PDF

Info

Publication number
KR20240001198A
KR20240001198A KR1020237040448A KR20237040448A KR20240001198A KR 20240001198 A KR20240001198 A KR 20240001198A KR 1020237040448 A KR1020237040448 A KR 1020237040448A KR 20237040448 A KR20237040448 A KR 20237040448A KR 20240001198 A KR20240001198 A KR 20240001198A
Authority
KR
South Korea
Prior art keywords
ndv
protein
apmv
nucleotide sequence
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040448A
Other languages
English (en)
Korean (ko)
Inventor
아돌포 가르시아-사스트레
이그나시오 메나
피터 팔레스
플로리안 크래머
웨이나 선
Original Assignee
이칸 스쿨 오브 메디슨 엣 마운트 시나이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이칸 스쿨 오브 메디슨 엣 마운트 시나이 filed Critical 이칸 스쿨 오브 메디슨 엣 마운트 시나이
Publication of KR20240001198A publication Critical patent/KR20240001198A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237040448A 2021-04-26 2022-04-25 Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스 Pending KR20240001198A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163179994P 2021-04-26 2021-04-26
US63/179,994 2021-04-26
US202263302434P 2022-01-24 2022-01-24
US63/302,434 2022-01-24
PCT/US2022/026185 WO2022232052A1 (en) 2021-04-26 2022-04-25 Chimeric newcastle disease virus expressing apmv hn and f proteins

Publications (1)

Publication Number Publication Date
KR20240001198A true KR20240001198A (ko) 2024-01-03

Family

ID=83848644

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040448A Pending KR20240001198A (ko) 2021-04-26 2022-04-25 Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스

Country Status (9)

Country Link
US (1) US20240199705A1 (https=)
EP (1) EP4329886A4 (https=)
JP (1) JP2024514975A (https=)
KR (1) KR20240001198A (https=)
AU (1) AU2022267223A1 (https=)
CA (1) CA3215468A1 (https=)
CO (1) CO2023015564A2 (https=)
MX (1) MX2023012595A (https=)
WO (1) WO2022232052A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN117778471A (zh) * 2023-12-25 2024-03-29 华南农业大学 克服新城疫母源抗体影响的重组新城疫病毒载体及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112739359A (zh) * 2018-07-13 2021-04-30 西奈山伊坎医学院 Apmv及其用于治疗癌症的用途
WO2020037215A1 (en) * 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Also Published As

Publication number Publication date
WO2022232052A1 (en) 2022-11-03
EP4329886A1 (en) 2024-03-06
US20240199705A1 (en) 2024-06-20
EP4329886A4 (en) 2025-09-17
CA3215468A1 (en) 2022-11-03
JP2024514975A (ja) 2024-04-03
MX2023012595A (es) 2023-11-28
CO2023015564A2 (es) 2023-11-30
AU2022267223A9 (en) 2023-11-16
AU2022267223A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
RU2733832C1 (ru) Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
KR100702523B1 (ko) 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
AU2024201139A1 (en) Newcastle disease viruses and uses thereof
KR101715418B1 (ko) 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신
RU2733834C1 (ru) Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
KR101745029B1 (ko) 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법
CN104471064B (zh) 副粘病毒及其用途
CN104962581B (zh) 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株
CN112739359A (zh) Apmv及其用于治疗癌症的用途
RU2733831C1 (ru) Искусственный ген, кодирующий бицистронную структуру, образованную последовательностями рецептор-связующего домена гликопротеина S коронавируса SARS-CoV-2, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_SC2, обеспечивающая экспрессию искусственного гена и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_SC2, используемого для создания вакцины против коронавируса SARS-CoV-2
AU2021269903A1 (en) Recombinant vaccine against covid-19 based on a paramyxovirus viral vector
EP3856240A1 (en) Compositions and methods for making and using virus-like particles (vlps)
KR20240001198A (ko) Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스
KR20210126075A (ko) 키메라 rsv 및 hmpv f 단백질, 면역원성 조성물, 및 사용 방법
KR102154794B1 (ko) 조류 인플루엔자 바이러스 h9n2의 표면항원을 발현하는 뉴캣슬병 바이러스 발현 시스템 및 이를 이용한 조류 백신
KR101279636B1 (ko) 백신인 복제―결핍 ｒｎａ 바이러스
KR102154795B1 (ko) 조류 인플루엔자 바이러스 h5n6의 표면항원을 발현하는 뉴캣슬병 바이러스 발현 시스템 및 이를 이용한 조류 백신
AU2018392826A1 (en) Lassa vaccine
KR102154796B1 (ko) 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
Baron et al. Development of a helper cell-dependent form of peste des petits ruminants virus: a system for making biosafe antigen
US20250250304A1 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
CN118139982A (zh) 表达apmv hn和f蛋白的嵌合新城疫病毒
AU2020348973A1 (en) Recombinant oncolytic Newcastle Disease Viruses with increased activity
CA3125370A1 (en) Recombinant oncolytic newcastle disease viruses with increased activity
JP3732204B2 (ja) 自律複製能を有する（−）鎖ｒｎａウイルスベクター

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250423

Comment text: Request for Examination of Application